T. Rowe Price Associates’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-21,972
| Closed | -$355K | – | 3040 |
|
|
2024
Q3 | $355K | Sell |
21,972
-4,090
| -16% | -$66.1K | ﹤0.01% | 2403 |
|
|
2024
Q2 | $637K | Sell |
26,062
-227,459
| -90% | -$5.56M | ﹤0.01% | 2092 |
|
|
2024
Q1 | $18.2M | Sell |
253,521
-173,173
| -41% | -$12.4M | ﹤0.01% | 993 |
|
|
2023
Q4 | $84.8M | Sell |
426,694
-15,786
| -4% | -$3.14M | 0.01% | 578 |
|
|
2023
Q3 | $58.8M | Buy |
442,480
+6,511
| +1% | +$866K | 0.01% | 635 |
|
|
2023
Q2 | $65.2M | Buy |
435,969
+21,485
| +5% | +$3.21M | 0.01% | 623 |
|
|
2023
Q1 | $60.8M | Sell |
414,484
-6,127
| -1% | -$899K | 0.01% | 629 |
|
|
2022
Q4 | $66.6M | Buy |
420,611
+35,643
| +9% | +$5.65M | 0.01% | 587 |
|
|
2022
Q3 | $74.1M | Sell |
384,968
-156,867
| -29% | -$30.2M | 0.01% | 546 |
|
|
2022
Q2 | $79.1M | Buy |
541,835
+44,997
| +9% | +$6.57M | 0.01% | 730 |
|
|
2022
Q1 | $87.4M | Buy |
496,838
+3,377
| +0.7% | +$594K | 0.01% | 775 |
|
|
2021
Q4 | $145M | Buy |
493,461
+5,689
| +1% | +$1.67M | 0.01% | 650 |
|
|
2021
Q3 | $121M | Buy |
487,772
+38,597
| +9% | +$9.59M | 0.01% | 702 |
|
|
2021
Q2 | $114M | Buy |
449,175
+126,694
| +39% | +$32.2M | 0.01% | 737 |
|
|
2021
Q1 | $57.3M | Sell |
322,481
-705
| -0.2% | -$125K | 0.01% | 960 |
|
|
2020
Q4 | $51.1M | Sell |
323,186
-5,317
| -2% | -$840K | 0.01% | 955 |
|
|
2020
Q3 | $84.6M | Buy |
328,503
+149,639
| +84% | +$38.5M | 0.01% | 710 |
|
|
2020
Q2 | $41.5M | Buy |
178,864
+16,228
| +10% | +$3.77M | 0.01% | 909 |
|
|
2020
Q1 | $27.1M | Buy |
162,636
+14,732
| +10% | +$2.45M | ﹤0.01% | 970 |
|
|
2019
Q4 | $31.9M | Buy |
+147,904
| New | +$31.9M | ﹤0.01% | 1047 |
|